ESMO 2025 – Lilly strengthens Verzenio’s case
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
The predictable failure of trilaciclib
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
